Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

PRIMARY OBJECTIVES:

I. To develop a mechanism for tracking and retaining patients enrolled on Children's Oncology
Group (COG) protocols.

II. To maintain regular, lifetime contact with patients in order to obtain current
identification and contact information, and self/parent-reported health status.

III. To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols
targeted for follow-up by the Long-Term Follow-Up Center (LTFC).

IV. To provide current patient contact information and self/parent-reported health status
updates to the COG Statistics and Data Center (SDC) and to each patient?s COG institution.

V. To facilitate collection of protocol-specific outcome data through collaboration with the
LTFC Oversight Committee, the SDC, and the member institutions.

OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions.

Approximately 6 months after completion of therapy patients receive a mailed packet
introducing the Long-Term Follow-Up Center (LTFC) and containing information related to their
individualized, protocol-specific follow-up guidelines. Patients are asked to complete a
patient response form, verify information provided in packet, update contact information, and
complete a Health Status Update Form. The Health Status Update Form is a brief document
including questions about current health status, disease status, and cancer therapy received
since the last mailing. Patients receive protocol-specific automatic reminders, and may
respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.

Inclusion Criteria:

- The patient must be enrolled on a frontline COG therapeutic trial for treatment of a
primary malignancy and is nearing completion of or has recently completed protocol
treatment (within the past 180 days)*; or the patient must have been enrolled on a COG
(or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term
follow-up by ALTE05N1

- Hodgkin lymphoma

- CCG 5942

- POG 9425

- POG 9426

- AHOD0031

- Brain tumor

- A9961

- Acute lymphoblastic leukemia

- POG 9404

- Osteosarcoma

- POG 9754

- Stem cell transplantation

- ASCT0631D

- Rhabdomyosarcoma

- IRS-III

- IRS-IV

- Note: For purposes of enrollment onto this study, completion of treatment is
defined as the date protocol therapy was terminated as reported (or will be
reported) on this patient?s last ?Reporting Period Worksheet/CRF? for their
frontline therapeutic protocol; patients become eligible as they approach this
date, and remain eligible for 180 days following the date that protocol therapy
was terminated; early termination of protocol therapy per the decision of the
patient, family and/or investigator does NOT preclude enrollment on this study

- Note: For purposes of eligibility for ALTE05N1, ?early termination of protocol
therapy? means that the patient has finished protocol therapy and will not
receive further treatment; patients whose therapy is terminated early due to
toxicity or who opt out of an end-of-therapy randomization (e.g., randomization
to continue with an experimental agent versus [vs.] no further treatment) are
eligible because they will not be receiving further therapy; however, a patient
who is removed from protocol therapy or opts to discontinue protocol
participation early in the course of treatment (e.g., following Induction) is not
eligible

- The patient must reside in the U.S. on the date of enrollment to ALTE05N1

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met